Clarify Consortium Decision Rights Before Discussing Shared Tool Terms

A consortium call rarely has one buyer sitting on it. The person coordinating the group speaks for several institutions, but that does not mean they can approve a deal, or even agree to start an evaluation, on behalf of all of them. For a Research Account Executive covering biotechnology accounts, the mistake usually happens early, in the first or second call, when the coordinator's confidence gets mistaken for authority. The fix is not a sharper pitch. It is a clear map of who actually holds each decision, built before you let the conversation drift toward pricing or commitments.

Why This Conversation Goes Wrong

A consortium call feels like a single stakeholder call. One person runs the meeting, answers questions fluently, and speaks about "our group" as if it were one entity. That fluency is easy to mistake for a mandate. In reality, a consortium coordinator usually manages logistics and communication between member institutions, not their purchasing decisions. Each university, institute, or lab in the group keeps its own procurement rules, its own legal review, and its own technical evaluation team.

The account executive who skips past this detail ends up negotiating with the wrong person. Worse, once a number gets discussed on that call, it spreads. The coordinator repeats it to members who never asked for it, some members treat it as a quote they can hold you to, and others get annoyed that terms were floated before they even confirmed interest. One member's enthusiasm does not bind the rest, and pretending otherwise creates a false sense of consensus that falls apart the moment procurement or legal at another institution gets involved.

How to Prepare Before the Call

Before you talk terms with anyone in a consortium, build a simple map. List which members are actively exploring the tool, which are only observing for now, and which have not engaged at all. For each active member, note who owns the technical evaluation, who owns procurement, and who has to sign off legally. In biotechnology accounts, this often means separating a lab director who wants to test a shared platform from a procurement office that enforces a purchasing threshold, and from a legal team that reviews data sharing or compliance terms for shared instruments or reagents.

Write down the open questions instead of assuming answers. Ask which members are actively considering the project. Ask whether their purchasing policies differ from one another. Ask what each institution needs internally before it can move from interest to a real evaluation. If you cannot answer these questions from your notes, you are not ready to discuss commercial terms, no matter how organized the coordinator sounds. This is the same discipline that matters in other biotechnology conversations, like knowing when to point a customer to approved documentation instead of answering from memory, as covered in Respond to a Consumable Equivalency Request With Approved Information. The common thread is simple. Do not answer a question that belongs to a different process just because someone asked it directly.

What to Say When the Coordinator Pushes for One Price

Here is how this plays out in practice. The consortium manager says, "Every member is asking me the same thing. Can you just give me one price that all of them can accept, so I can stop fielding separate questions?"

The account executive answers, "I cannot offer terms until the appropriate commercial review happens, and that review depends on each institution's own process. Before we get there, can we document which members actually want to explore this, who owns the decision at each one, and what a shared evaluation would need to answer for them to move forward?"

The manager pauses, then says, "Fair enough. Honestly, one of the universities is only sitting in to observe right now, they have not committed to anything. And the other one has a separate purchasing threshold review that kicks in above a certain contract size, so they will need more time regardless of what number we land on."

That single exchange just saved the account executive from quoting a price that half the group was never authorized to accept. It also gave the executive two concrete facts to work with, an observer that needs to be reclassified and a threshold review that changes the timeline for one member. Neither fact was visible before the executive refused to answer the wrong question.

Mistakes to Avoid

The most common mistake is treating an early interest call as proof that every member will participate. It is not. A second mistake is quoting one price for the whole group before confirming that the group even has a shared purchasing process. Some consortiums do, many do not. A third mistake is letting a vague answer about a member's status go unchallenged. If the coordinator says "everyone's on board" without naming names, ask directly which institutions have confirmed and which have not.

A fourth mistake is skipping the stakeholder map entirely because the coordinator seems organized and easy to talk to. Organized and authorized are not the same thing. And a fifth mistake is confusing exploration with approval, then building a proposal timeline around a date nobody actually confirmed. The same pattern shows up when a customer wants an immediate answer on something that actually requires escalation, which is why the discipline of routing a question to the right owner instead of answering it yourself matters in other biotechnology conversations too, including the one covered in Respond to a Consumable Storage Deviation With the Right Escalation.

How to Practice and Score This Conversation

Run a roleplay with three fictional institutions in the consortium. Give the account executive a scenario where one is actively evaluating, one is observing only, and one has a distinct procurement threshold. Ask the executive to label, without guessing, who owns exploration, who owns technical evaluation, who owns procurement, and who owns final approval at each institution. Score the roleplay on whether the executive asked open questions before offering any commercial detail, and on whether they resisted the pull to answer a pricing question with a single number.

After the roleplay, review the stakeholder map with a manager and pick one specific next meeting that advances a real open question, such as confirming the threshold review timeline with the member that flagged it. A manager can also assign this scenario as one of several Biotechnology practice conversations so the executive builds the same habit across different account situations, not just this one. DealSpeak scores these calls on whether the executive separated exploration from commitment, which is the exact skill this conversation demands.

Getting this right protects the relationship more than any pricing concession would. When a consortium sees its own governance reflected back accurately, the coordinator trusts you to represent the process correctly, and individual members trust that you are not trying to rush their internal reviews. That trust is worth more than a fast answer on price.